ABSTRACT
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shionogi alone. By virtue of In vitro activity against carbapenem-resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC) type enzymes or metallo-beta-lactamases (e.g. New Delhi metallo-beta-lactamase [NDM]), plus activity against carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, the antibiotic has enormous promise. Initiation of phase III trials for treatment of CRE commenced in March 2016.
